Berenberg Bank reaffirmed their buy rating on shares of GSK (LON:GSK – Free Report) in a research report report published on Tuesday, Digital Look reports. Berenberg Bank currently has a GBX 1,820 ($23.80) price objective on the stock.
GSK has been the subject of a number of other reports. JPMorgan Chase & Co. reaffirmed an underweight rating on shares of GSK in a report on Monday, July 29th. Deutsche Bank Aktiengesellschaft reiterated a buy rating and set a GBX 1,850 ($24.19) price target on shares of GSK in a research report on Tuesday, September 3rd. Shore Capital reissued a buy rating on shares of GSK in a report on Wednesday, August 28th. Jefferies Financial Group reaffirmed a buy rating and issued a GBX 2,100 ($27.46) target price on shares of GSK in a research note on Thursday, June 27th. Finally, Citigroup lowered their price target on shares of GSK from GBX 2,120 ($27.72) to GBX 1,900 ($24.85) and set a buy rating for the company in a report on Friday, July 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of GBX 1,805.71 ($23.61).
GSK Price Performance
GSK Dividend Announcement
The business also recently disclosed a dividend, which will be paid on Thursday, October 10th. Investors of record on Thursday, August 15th will be paid a dividend of GBX 15 ($0.20) per share. The ex-dividend date is Thursday, August 15th. This represents a dividend yield of 0.97%. GSK’s dividend payout ratio (DPR) is presently 5,309.73%.
Insider Buying and Selling at GSK
In related news, insider Wendy Becker bought 446 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was bought at an average cost of GBX 1,614 ($21.11) per share, for a total transaction of £7,198.44 ($9,413.42). Insiders own 1.61% of the company’s stock.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
- Five stocks we like better than GSK
- What Are Dividend Contenders? Investing in Dividend Contenders
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- Why is the Ex-Dividend Date Significant to Investors?
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.